PDF(Pubmed)
Abstract：
Alzheimer\'s disease (AD) is a stealthy and progressive neurological disorder that is a leading cause of dementia in the global elderly population, imposing a significant burden on both the elderly and society. Currently, the condition is treated with medications that alleviate symptoms. Nonetheless, these drugs may not consistently produce the desired results and can cause serious side effects. Hence, there is a vigorous pursuit of alternative options to enhance the quality of life for patients. Ginkgo biloba (GB), an herb with historical use in traditional medicine, contains bioactive compounds such as terpenoids (Ginkgolides A, B, and C), polyphenols, organic acids, and flavonoids (quercetin, kaempferol, and isorhamnetin). These compounds are associated with anti-inflammatory, antioxidant, and neuroprotective properties, making them valuable for cognitive health. A systematic search across three databases using specific keywords-GB in AD and dementia-yielded 1702 documents, leading to the selection of 15 clinical trials for synthesis. In eleven studies, GB extract/EGb 761® was shown to improve cognitive function, neuropsychiatric symptoms, and functional abilities in both dementia types. In four studies, however, there were no significant differences between the GB-treated and placebo groups. Significant improvements were observed in scores obtained from the Mini-Mental State Examination (MMSE), Short Cognitive Performance Test (SKT), and Neuropsychiatric Inventory (NPI). While the majority of synthesized clinical trials show that Ginkgo biloba has promising potential for the treatment of these conditions, more research is needed to determine optimal dosages, effective delivery methods, and appropriate pharmaceutical formulations. Furthermore, a thorough assessment of adverse effects, exploration of long-term use implications, and investigation into potential drug interactions are critical aspects that must be carefully evaluated in future studies.
摘要：
阿尔茨海默病(AD)是一种隐秘的进行性神经系统疾病,是全球老年人群痴呆的主要原因,给老年人和社会带来了巨大的负担。目前,这种情况是用缓解症状的药物治疗。尽管如此，这些药物可能无法持续产生预期的结果，并可能导致严重的副作用。因此，积极寻求替代选择，以提高患者的生活质量。银杏(GB),一种在传统医学中具有历史用途的草药，含有生物活性化合物，如萜类化合物(银杏内酯A，B,andC),多酚，有机酸,和类黄酮（槲皮素，山奈酚,和isorhamnetin）。这些化合物与抗炎有关，抗氧化剂，和神经保护特性，使它们对认知健康有价值。在三个数据库中使用特定关键字进行系统搜索-AD中的GB和痴呆症产生的1702个文档，导致选择15项临床试验进行合成。在11项研究中，GB提取物/EGB761®被证明可以改善认知功能，神经精神症状,和两种痴呆症类型的功能能力。在四项研究中，然而,GB治疗组和安慰剂组之间无显著差异.从迷你精神状态检查（MMSE）获得的分数显着改善，短期认知表现测试(SKT)，和神经精神量表(NPI)。虽然大多数合成临床试验表明银杏叶具有治疗这些疾病的潜力，需要更多的研究来确定最佳剂量，有效的交付方法，和适当的药物制剂。此外，全面评估不良反应，探索长期使用的影响，和调查潜在的药物相互作用是关键方面,必须在未来的研究中仔细评估.
